Peptide |
AuNPs |
PTT |
Enhances the PTT efficiency of gold nanoparticles for furin-related cancer |
MDA-MB-468 cell |
[106] |
pH-sensitively zwitterionic polypeptide conjugated GNRs |
PTT |
Excellent biocompatibility against normal and cell pH-sensitively released the drugs under tumoral acid condition |
HeLa cells |
[107] |
cRGD@TAT-DINPs |
CT/PTT/PDT |
Excellent biological stability, combining multiple treatment methods |
MDA-MB-231 and A549 cell |
[131] |
CD133-Pyro |
PDT |
More effective targeted and intraocyric accumulation effects |
Colorectal cancer cells |
[132] |
IR780-M-APP NPs |
PDT/immunotherapy |
Targeted tumors and eradicated the metastatic and invasive tumors effectively |
B16F10 cell |
[134] |
Protein |
E72-Chitosan-Ag3AuS2 hybrid hydrogel |
PTT |
High biocompatibility and photothermal conversion efficiency |
Tongue cancer cell |
[109] |
BSA-Ag2S NPs |
PTT |
Biocompatibility |
HeLa cells |
[110] |
Tf-RuNPs |
PTT |
Biocompatibility and stability |
HEK-293 cell |
[111] |
Ce6/Cyt c @ZIF-8/HA NPs |
PDT |
Overcomes the PDT induced hypoxia to further increase PDT efficiency |
HeLa cell and SMMC7721 cell |
[135] |
Bioinspired oxygen nanocarrier (C@HPOC) |
PDT |
Destroyed the primary tumors and effectively inhibited distant tumors and lung metastasis |
4T1 tumor cells |
[136] |
FA/PtBSA@MB-MSNS nanopolymers |
PDT |
Overcomes the PDT induced hypoxia to further increase PDT efficiency |
4T1 tumor cells |
[137] |
PDA |
PhMOSN@DOX-HA |
PTT/CL |
Biocompatible and biodegradable |
4T1 tumor cell |
[114] |
MoSe2@PDA nanocomposites |
PTT/CL |
High loading efficiency and pH-responsive Dox release effect |
U14 cell |
[115] |
PDA@DOX NPs |
PTT/CL |
Targeted and high drug load |
4 T1 tumor cell |
[116] |
PDA-Dox-Pc-QRH NPs |
PDT/CT |
Chemical photodynamic combined targeted therapy |
A431 cell |
[138] |
MnO2-PDA nanoshell |
PDT/CT |
Has the effect of alleviating tumor hypoxia and enhancing the PDT effect |
B16F10 cell |
[139] |
RNA |
CuS-RNP/DOX@PEI |
PTT/GT/ CT |
Provides a potential strategy to reduce tumor thermal tolerance for enhanced mild-PTT effects |
A375 cell |
[119] |
PPTC/siRNA |
PDT |
ROS-responsive siRNA release mode, PDT combined with RNAi to improve the therapeutic efficiency |
HepG2 cells |
[144] |
DNA |
DNA-UCNP-Au hydrogels |
PTT |
Low cytotoxicity and injectable properties allow local therapy to precisely target the tumor site |
T24 bladder cancer cell |
[121] |
UCNP-ApDz-TMPyP4 Nanoplatform |
PTT |
Combining PDT with gene therapy shows excellent antitumor effect |
Catalysis |
[141] |
DNA Nanosponge |
PDT/GT |
Effective against hypoxia-related photodynamic resistance during PDT in vivo with good biocompatibility |
HeLa cells |
[142] |
Enzyme |
GOIGLs (GOx) |
PTT |
Achieves milder PTT with good biocompatibility |
A549 cell |
[124] |
PMF−GOx |
PTT/CDT |
Fenton reaction and moderatehyperthermia cancer treatment together |
MCF-7 tumor cell |
[125] |
NC@GOx NPs |
PTT/CDT |
Combination therapy of starvation therapy, PTT and CDT for tumors |
4T1 tumor cell |
[126] |
MYR@HGNs (MYR) |
PTT |
Protect and activate the encapsulated enzymes for localized chemo-photothermal therapy |
4T1 tumor cell |
[127] |
HA-CAT@aCe6 (CAT)) |
PDT |
Overcome tumor cell hypoxia during PDT and improve the therapeutic effect of PDT |
MDA-MB-231 cell |
[146] |
GOx-MSN@MnPc-LP |
PDT |
Good enzyme activity, and good therapeutic effect and safety through the synergistic treatment |
4T1 tumor cell |
[147] |
nanogel |
PDT |
Provide a new method for constructing combinatorial therapeutics with good tumor targeting ability and efficient anti-cancer effect |
4T1 tumor cell |
[148] |